In our previous clinical studies, we observed that breast cancer patients [3, 12] receiving doxorubicin and cyclophosphamide reported self-perceived concentration deficits during chemotherapy, and patients experiencing the least reduction of plasma BDNF levels between baseline and end of chemotherapy were most protected from cognitive decline. Here, BDNF is linked to breast carcinoma.